Overview

A Phase 2, Double-blind Study to Evaluate Immunogenicity and Safety of Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult Volunteers

Status:
Completed

Trial end date:
2018-10-30

Target enrollment:

Participant gender:

Summary

The objectives of this phase 2 study are to evaluate immunogenicity, safety and tolerability of AD07030, a trivalent influenza virus antigens vaccine, given intranasally in 2 doses in healthy adult volunteers.

Phase:

Phase 2

Details

Lead Sponsor:

Advagene Biopharma Co. Ltd.

Treatments:

Vaccines